好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2026 Annual Meeting | Industry Therapeutic Update from C2N Diagnostics: Diagnostic Precision in Alzheimer's Disease: A Discussion on the Clinical Integration of Blood Biomarker Testing

Tuesday 04/21/26
06:00 PM - 08:00 PM CDT Add To Calendar
This program will be presented in-person only
This program is not expected to be available in the meeting's On Demand product.
Industry Therapeutic Update
Joel Braunstein
General Neurology
This program brings together clinicians to discuss current and emerging innovations in Alzheimer's disease diagnostics, with a focus on blood-based tests in clinical practice. The speakers will examine the role of blood tests can provide for identifying amyloid pathology and considerations for utilization in diagnostic evaluation. The session will highlight opportunities for blood tests in Alzheimer's disease assessment, current approaches to clinical decision-making, and practical perspectives on diagnosing Alzheimer's
No CME available
Event Timeline
06:00 PM - 08:00 PM CDT Speaker Industry Therapeutic Update from C2N Diagnostics: Diagnostic Precision in Alzheimer's Disease: A Discussion on the Clinical Integration of Blood Biomarker Testing
Faculty Disclosures
Joel Braunstein Dr. Braunstein has received personal compensation for serving as an employee of C2N Diagnostics. Dr. Braunstein has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for C2N Diagnositcs.